Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zalcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.57 |
| ▸ | ALB | P02768 | 3/20 | 0.57 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.57 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.57 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.57 |
| ▸ | POLG | P54098 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zalcitabine SCHEMBL211115 | 1.00 | ABL1 (0.57) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL6913582 | 0.95 | ABL1 (0.55) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL12149465 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL598496 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL3715526 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL21100417 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL3235525 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL3598 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL8094882 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB | |
| Zalcitabine SCHEMBL9194365 | 0.95 | LMNA (0.62) | ABL1RIN1LMNAPDE3AALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014031954-A1 | HOMOPOLYMER MEDIATED NUCLEIC ACID AMPLIFICATION | TUFTS UNIVERSITY (US) | 2014-02-27 | — | — | WO | claimed |
| EP-2428201-A1 | Oral administration of nucleoside monophosphates | Merck Serono S.A. (CH) | 2012-03-14 | — | — | EP | claimed |
| US-6498036-B1 | Methods of targeting a chromosomal gene sequence in a eukaryotic cell | TRUSTEES OF AMHERST COLLEGE | 2002-12-24 | — | — | US | claimed |
| EP-2614156-B1 | CONTROL OF DNA MOVEMENT IN A NANOPORE AT ONE NUCLEOTIDE PRECISION BY A PROCESSIVE ENZYME | UNIV CALIFORNIA (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9914950-B2 | Homopolymer mediated nucleic acid amplification | TUFTS UNIVERSITY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20150203887-A1 | HOMOPOLYMER MEDIATED NUCLEIC ACID AMPLIFICATION | TUFTS UNIVERSITY (US) | 2015-07-23 | — | — | US | disclosed |
| WO-2014031954-A1 | HOMOPOLYMER MEDIATED NUCLEIC ACID AMPLIFICATION | TUFTS UNIVERSITY (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2614156-A2 | CONTROL OF DNA MOVEMENT IN A NANOPORE AT ONE NUCLEOTIDE PRECISION BY A PROCESSIVE ENZYME | The Regents of the University of California (US) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012033524-A2 | CONTROL OF DNA MOVEMENT IN A NANOPORE AT ONE NUCLEOTIDE PRECISION BY A PROCESSIVE ENZYME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | WO | disclosed |
| EP-2428201-A1 | Oral administration of nucleoside monophosphates | Merck Serono S.A. (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-1240355-B1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | CAMBREX BIO SCIENCE ROCKLAND I (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-1995029702-A1 | TEXAPHYRIN SOLID-SUPPORTS AND DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1994009003-A1 | SAPPHYRIN DERIVATIVES, CONJUGATES AND POLYMERS THEREOF AND EXPANDED PORPHYRIN CHROMATOGRAPHIC SUPPORTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5223263-A | Viricide complex; aids therapy | VICAL, INC. (US) | 1993-06-29 | — | — | US | disclosed |
| WO-1992022306-A1 | TRANSFORMED ERYTHROCYTES, PROCESS FOR PREPARING THE SAME, AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE) (LU) | 1992-12-23 | — | — | WO | disclosed |
| EP-0517986-A1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE) (LU) | 1992-12-16 | — | — | EP | disclosed |
| WO-1990000555-A1 | LIPID DERIVATIVES OF ANTIVIRAL NUCLEOSIDES, LIPOSOMAL INCORPORATION AND METHOD OF USE | VICAL, INC. (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0350287-A2 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | NeXstar Pharmaceuticals, Inc. (US) | 1990-01-10 | — | — | EP | disclosed |
| WO-1988007854-A1 | NEW ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEM | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1988-10-20 | — | — | WO | disclosed |
| EP-0286418-A1 | Anti-retroviral agents and delivery systems for the same | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1988-10-12 | — | — | EP | disclosed |